Laboratory and Genetic Investigation of Mutations Accounting for Congenital Fibrinogen Disorders

 

 Buy Article Permissions and Reprints

Abstract

Congenital fibrinogen disorders are classified into two types of plasma fibrinogen defects: type I (quantitative fibrinogen deficiencies), that is, hypofibrinogenemia or afibrinogenemia, in which there are low or absent plasma fibrinogen antigen levels, respectively, and type II (qualitative fibrinogen deficiencies), that is, dysfibrinogenemia or hypodysfibrinogenemia, in which there are normal or reduced antigen levels associated with disproportionately low functional activity. These disorders are caused by mutations in the three fibrinogen-encoding genes FGA, FGB, and FGG. Afibrinogenemia is associated with mild to severe bleeding, whereas hypofibrinogenemia is often asymptomatic. For these quantitative disorders, the majority of mutations prevent protein production. However, in some cases, missense or late-truncating nonsense mutations allow synthesis of the mutant fibrinogen chain, but intracellular fibrinogen assembly and/or secretion are impaired. Qualitative fibrinogen disorders are associated with bleeding, thrombosis, or both thrombosis and bleeding, but many dysfibrinogenemias are asymptomatic. The majority of cases are caused by heterozygous missense mutations. Here, we review the laboratory and genetic diagnosis of fibrinogen gene anomalies with an updated discussion of causative mutations identified.

• References

• 1 Neerman-Arbez M, de Moerloose P. Hereditary fibrinogen abnormalities. In: Kaushansky K, Lichtman M, Beutler E, et al, eds. Williams Hematology. 8th ed. New York, NY: McGraw-Hill; 2010: 1-33
  Google Scholar
• 2 Tennent GA, Brennan SO, Stangou AJ, O'Grady J, Hawkins PN, Pepys MB. Human plasma fibrinogen is synthesized in the liver. Blood 2007; 109 (5) 1971-1974
  CrossrefPubMedGoogle Scholar
• 3 Medved L, Weisel JW ; Fibrinogen and Factor XIII Subcommittee of Scientific Standardization Committee of International Society on Thrombosis and Haemostasis. Recommendations for nomenclature on fibrinogen and fibrin. J Thromb Haemost 2009; 7 (2) 355-359
  CrossrefPubMedGoogle Scholar
• 4 de Moerloose P, Casini A, Neerman-Arbez M. Congenital fibrinogen disorders: an update. Semin Thromb Hemost 2013; 39 (6) 585-595
  Article in Thieme ConnectPubMedGoogle Scholar
• 5 Palla R, Peyvandi F, Shapiro AD. Rare bleeding disorders: diagnosis and treatment. Blood 2015; 125 (13) 2052-2061
  CrossrefPubMedGoogle Scholar
• 6 Peyvandi F, Menegatti M, Palla R. Rare bleeding disorders: worldwide efforts for classification, diagnosis, and management. Semin Thromb Hemost 2013; 39 (6) 579-584
  Article in Thieme ConnectPubMedGoogle Scholar
• 7 Casini A, de Moerloose P, Neerman-Arbez M. Clinical features and management of congenital fibrinogen deficiencies. Semin Thromb Hemost 2016; 42 (4) 356-365
  Article in Thieme ConnectPubMedGoogle Scholar
• 8 Cunningham MT, Brandt JT, Laposata M, Olson JD. Laboratory diagnosis of dysfibrinogenemia. Arch Pathol Lab Med 2002; 126 (4) 499-505
  PubMedGoogle Scholar
• 9 Mackie IJ, Kitchen S, Machin SJ, Lowe GD ; Haemostasis and Thrombosis Task Force of the British Committee for Standards in Haematology. Guidelines on fibrinogen assays. Br J Haematol 2003; 121 (3) 396-404
  CrossrefPubMedGoogle Scholar
• 10 Casini A, Sokollik C, Lukowski SW , et al. Hypofibrinogenemia and liver disease: a new case of Aguadilla fibrinogen and review of the literature. Haemophilia 2015; 21 (6) 820-827
  CrossrefPubMedGoogle Scholar
• 11 Casini A, Neerman-Arbez M, Ariëns RA, de Moerloose P. Dysfibrinogenemia: from molecular anomalies to clinical manifestations and management. J Thromb Haemost 2015; 13 (6) 909-919
  CrossrefPubMedGoogle Scholar
• 12 Miesbach W, Schenk J, Alesci S, Lindhoff-Last E. Comparison of the fibrinogen Clauss assay and the fibrinogen PT derived method in patients with dysfibrinogenemia. Thromb Res 2010; 126 (6) e428-e433
  CrossrefPubMedGoogle Scholar
• 13 Shapiro SE, Phillips E, Manning RA , et al. Clinical phenotype, laboratory features and genotype of 35 patients with heritable dysfibrinogenaemia. Br J Haematol 2013; 160 (2) 220-227
  CrossrefPubMedGoogle Scholar
• 14 Llamas P, Santos AB, Outeiriño J, Soto C, Tomás JF. Diagnostic utility of comparing fibrinogen Clauss and prothrombin time derived method. Thromb Res 2004; 114 (1) 73-74
  CrossrefPubMedGoogle Scholar
• 15 Lefkowitz JB, DeBoom T, Weller A, Clarke S, Lavrinets D. Fibrinogen Longmont: a dysfibrinogenemia that causes prolonged clot-based test results only when using an optical detection method. Am J Hematol 2000; 63 (3) 149-155
  CrossrefPubMedGoogle Scholar
• 16 Jennings I, Peyvandi F, Kitchen S , et al. A failure to diagnosis dysfibrinogenaemia: data from multicentre studies amongst UK Nequas and proRBDD project laboratories. In: XXV Congress of the International Society on Thrombosis and Haemostasis, Abstract PO500. Toronto, Canada; June 2015
  PubMedGoogle Scholar
• 17 Casini A, Blondon M, Lebreton A , et al. Natural history of patients with congenital dysfibrinogenemia. Blood 2015; 125 (3) 553-561
  CrossrefPubMedGoogle Scholar
• 18 Krammer B, Anders O, Nagel HR, Burstein C, Steiner M. Screening of dysfibrinogenaemia using the fibrinogen function versus antigen concentration ratio. Thromb Res 1994; 76 (6) 577-579
  CrossrefPubMedGoogle Scholar
• 19 Peyvandi F. Results of an international, multicentre pharmacokinetic trial in congenital fibrinogen deficiency. Thromb Res 2009; 124 (Suppl. 02) S9-S11
  CrossrefPubMedGoogle Scholar
• 20 de Moerloose P, Boehlen F, Neerman-Arbez M. Fibrinogen and the risk of thrombosis. Semin Thromb Hemost 2010; 36 (1) 7-17
  Article in Thieme ConnectPubMedGoogle Scholar
• 21 Dupuy E, Soria C, Molho P , et al. Embolized ischemic lesions of toes in an afibrinogenemic patient: possible relevance to in vivo circulating thrombin. Thromb Res 2001; 102 (3) 211-219
  CrossrefPubMedGoogle Scholar
• 22 Ariëns RA. Fibrin(ogen) and thrombotic disease. J Thromb Haemost 2013; 11 (Suppl. 01) 294-305
  CrossrefPubMedGoogle Scholar
• 23 Sugo T, Endo H, Matsuda M , et al. A classification of the fibrin network structures formed from the hereditary dysfibrinogens. J Thromb Haemost 2006; 4 (8) 1738-1746
  CrossrefPubMedGoogle Scholar
• 24 Collet JP, Soria J, Mirshahi M , et al. Dusart syndrome: a new concept of the relationship between fibrin clot architecture and fibrin clot degradability: hypofibrinolysis related to an abnormal clot structure. Blood 1993; 82 (8) 2462-2469
  PubMedGoogle Scholar
• 25 Westbury SK, Duval C, Philippou H , et al. Partial deletion of the αC-domain in the Fibrinogen Perth variant is associated with thrombosis, increased clot strength and delayed fibrinolysis. Thromb Haemost 2013; 110 (6) 1135-1144
  Article in Thieme ConnectPubMedGoogle Scholar
• 26 Pieters M, Undas A, Marchi R, De Maat MP, Weisel J, Ariëns RA ; Factor XIII And Fibrinogen Subcommittee Of The Scientific Standardisation Committee Of The International Society For Thrombosis And Haemostasis. An international study on the standardization of fibrin clot permeability measurement: methodological considerations and implications for healthy control values. J Thromb Haemost 2012; 10 (10) 2179-2181
  CrossrefPubMedGoogle Scholar
• 27 Sugo T, Nakamikawa C, Yoshida N , et al. End-linked homodimers in fibrinogen Osaka VI with a B beta-chain extension lead to fragile clot structure. Blood 2000; 96 (12) 3779-3785
  PubMedGoogle Scholar
• 28 Undas A, Pastuszczak M, Iwaniec T, Kapelak K, Neerman-Arbez M. Functional characterisation of plasma fibrin clots in Polish carriers of fibrinogen gammaArg275His mutation (fibrinogen Zabrze). Thromb Haemost 2010; 104 (2) 415-417
  Article in Thieme ConnectPubMedGoogle Scholar
• 29 Galanakis DK, Neerman-Arbez M, Brennan S , et al. Thromboelastographic phenotypes of fibrinogen and its variants: clinical and non-clinical implications. Thromb Res 2014; 133 (6) 1115-1123
  CrossrefPubMedGoogle Scholar
• 30 Kant JA, Fornace Jr AJ, Saxe D, Simon MI, McBride OW, Crabtree GR. Evolution and organization of the fibrinogen locus on chromosome 4: gene duplication accompanied by transposition and inversion. Proc Natl Acad Sci U S A 1985; 82 (8) 2344-2348
  CrossrefPubMedGoogle Scholar
• 31 de Maat MP, Verschuur M. Fibrinogen heterogeneity: inherited and noninherited. Curr Opin Hematol 2005; 12 (5) 377-383
  CrossrefPubMedGoogle Scholar
• 32 Blombäck M, Blombäck B, Mammen EF, Prasad AS. Fibrinogen Detroit—a molecular defect in the N-terminal disulphide knot of human fibrinogen?. Nature 1968; 218 (5137) 134-137
  CrossrefPubMedGoogle Scholar
• 33 Neerman-Arbez M, Honsberger A, Antonarakis SE, Morris MA. Deletion of the fibrinogen [correction of fibrogen] alpha-chain gene (FGA) causes congenital afibrogenemia. J Clin Invest 1999; 103 (2) 215-218
  CrossrefPubMedGoogle Scholar
• 34 Roberts HR, Stinchcombe TE, Gabriel DA. The dysfibrinogenaemias. Br J Haematol 2001; 114 (2) 249-257
  CrossrefPubMedGoogle Scholar
• 35 Galanakis D. Afibrinogenemias and dysfibrinogenemias. In: Marder V, White GC, Aird WC, eds. Hemostasis and Thrombosis: Basic Principles and Clinical Practice. 6th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2012: 693-708
  Google Scholar
• 36 Vu D, Neerman-Arbez M. Molecular mechanisms accounting for fibrinogen deficiency: from large deletions to intracellular retention of misfolded proteins. J Thromb Haemost 2007; 5 (Suppl. 01) 125-131
  CrossrefPubMedGoogle Scholar
• 37 Ebert RF. Index of Variant Human Fibrinogens. Boca Raton, Ann Arbor, Boston: CRC Press; 1994
  Google Scholar
• 38 Galanakis DK, Neerman-Arbez M, Kudryk B, Henschen A. Decreased plasmin resistance by clots of a homophenotypic Aalpha R 16H fibrinogen (Kingsport, slower fibrinopeptide A than fibrinopeptide B release). Blood Coagul Fibrinolysis 2010; 21 (2) 135-139
  CrossrefPubMedGoogle Scholar
• 39 Monaldini L, Asselta R, Duga S , et al. Mutational screening of six afibrinogenemic patients: identification and characterization of four novel molecular defects. Thromb Haemost 2007; 97 (4) 546-551
  PubMedGoogle Scholar
• 40 Neerman-Arbez M, Antonarakis SE, Honsberger A, Morris MA. The 11 kb FGA deletion responsible for congenital afibrinogenaemia is mediated by a short direct repeat in the fibrinogen gene cluster. Eur J Hum Genet 1999; 7 (8) 897-902
  CrossrefPubMedGoogle Scholar
• 41 Neerman-Arbez M, de Moerloose P, Honsberger A , et al. Molecular analysis of the fibrinogen gene cluster in 16 patients with congenital afibrinogenemia: novel truncating mutations in the FGA and FGG genes. Hum Genet 2001; 108 (3) 237-240
  CrossrefPubMedGoogle Scholar
• 42 Watanabe K, Shibuya A, Ishii E , et al. Identification of simultaneous mutation of fibrinogen alpha chain and protein C genes in a Japanese kindred. Br J Haematol 2003; 120 (1) 101-108
  CrossrefPubMedGoogle Scholar
• 43 Spena S, Duga S, Asselta R , et al. Congenital afibrinogenaemia caused by uniparental isodisomy of chromosome 4 containing a novel 15-kb deletion involving fibrinogen Aalpha-chain gene. Eur J Hum Genet 2004; 12 (11) 891-898
  CrossrefPubMedGoogle Scholar
• 44 Brennan SO, Maghzal G, Shneider BL, Gordon R, Magid MS, George PM. Novel fibrinogen gamma375 Arg—>Trp mutation (fibrinogen aguadilla) causes hepatic endoplasmic reticulum storage and hypofibrinogenemia. Hepatology 2002; 36 (3) 652-658
  CrossrefPubMedGoogle Scholar
• 45 Brennan SO, Wyatt J, Medicina D, Callea F, George PM. Fibrinogen brescia: hepatic endoplasmic reticulum storage and hypofibrinogenemia because of a gamma284 Gly—>Arg mutation. Am J Pathol 2000; 157 (1) 189-196
  CrossrefPubMedGoogle Scholar
• 46 Asselta R, Robusto M, Braidotti P , et al. Hepatic fibrinogen storage disease: identification of two novel mutations (p.Asp316Asn, fibrinogen Pisa and p.Gly366Ser, fibrinogen Beograd) impacting on the fibrinogen γ-module. J Thromb Haemost 2015; 13 (8) 1459-1467
  CrossrefPubMedGoogle Scholar
• 47 Dib N, Quelin F, Ternisien C , et al. Fibrinogen angers with a new deletion (gamma GVYYQ 346-350) causes hypofibrinogenemia with hepatic storage. J Thromb Haemost 2007; 5 (10) 1999-2005
  CrossrefPubMedGoogle Scholar
• 48 Brennan SO, Davis RL, Conard K, Savo A, Furuya KN. Novel fibrinogen mutation γ314Thr→Pro (fibrinogen AI duPont) associated with hepatic fibrinogen storage disease and hypofibrinogenaemia. Liver Int 2010; 30 (10) 1541-1547
  CrossrefPubMedGoogle Scholar
• 49 Asselta R, Platè M, Robusto M , et al. Clinical and molecular characterisation of 21 patients affected by quantitative fibrinogen deficiency. Thromb Haemost 2015; 113 (3) 567-576
  PubMedGoogle Scholar
• 50 Sumitha E, Jayandharan GR, Arora N , et al. Molecular basis of quantitative fibrinogen disorders in 27 patients from India. Haemophilia 2013; 19 (4) 611-618
  CrossrefPubMedGoogle Scholar
• 51 Chapin J, DeSancho M. Pulmonary embolism in a patient with congenital afibrinogenemia. Haemophilia 2013; 19 (6) e380-e382
  CrossrefPubMedGoogle Scholar
• 52 Kulkarni BP, Nair SB, Vijapurkar M , et al. Molecular pathology of rare bleeding disorders (RBDs) in India: a systematic review. PLoS ONE 2014; 9 (9) e108683
  CrossrefPubMedGoogle Scholar
• 53 Stikarová J, Blatný J, Kotlín R , et al. Novel homozygous fibrinogen Aα chain truncation causes severe afibrinogenemia with life threatening complications in a two-year-old boy. Thromb Res 2013; 132 (4) 490-492
  CrossrefPubMedGoogle Scholar
• 54 Zhang J, Zhao X, Wang Z , et al. A novel fibrinogen B beta chain frameshift mutation causes congenital afibrinogenaemia. Thromb Haemost 2013; 110 (1) 76-82
  Article in Thieme ConnectPubMedGoogle Scholar
• 55 Casini A, Lukowski S, Quintard VL , et al. FGB mutations leading to congenital quantitative fibrinogen deficiencies: an update and report of four novel mutations. Thromb Res 2014; 133 (5) 868-874
  CrossrefPubMedGoogle Scholar
• 56 Castaman G, Rimoldi V, Giacomelli SH, Duga S. Congenital hypofibrinogenemia associated with novel homozygous fibrinogen Aα and heterozygous Bβ chain mutations. Thromb Res 2015; 136 (1) 144-147
  CrossrefPubMedGoogle Scholar
• 57 Marchi R, Brennan S, Meyer M , et al. A novel mutation in the FGB: c.1105C>T turns the codon for amino acid Bβ Q339 into a stop codon causing hypofibrinogenemia. Blood Cells Mol Dis 2013; 50 (3) 177-181
  CrossrefPubMedGoogle Scholar
• 58 Riedelová-Reicheltová Z, Riedel T, Májek P , et al. Abnormal fibrinogen Zlín (γThr21Ile) with missense mutation causing hypofibrinogenemia. Acta Haematol 2014; 132 (2) 140-143
  CrossrefPubMedGoogle Scholar
• 59 Soya K, Takezawa Y, Okumura N, Terasawa F. Nonsense-mediated mRNA decay was demonstrated in two hypofibrinogenemias caused by heterozygous nonsense mutations of FGG, Shizuoka III and Kanazawa II. Thromb Res 2013; 132 (4) 465-470
  CrossrefPubMedGoogle Scholar
• 60 Brennan SO, Mangos H, Faed JM. Benign FGB (148Lys→Asn, and 448Arg→Lys), and novel causative γ211Tyr→His mutation distinguished by time of flight mass spectrometry in a family with hypofibrinogenaemia. Thromb Haemost 2014; 111 (4) 679-684
  PubMedGoogle Scholar
• 61 Kotlín R, Pastva O, Stikarová J , et al. Two novel mutations in the fibrinogen γ nodule. Thromb Res 2014; 134 (4) 901-908
  CrossrefPubMedGoogle Scholar
• 62 Zhu L, Wang Y, Zhao M , et al. Novel mutations (γTrp208Leu and γLys232Thr) leading to congenital hypofibrinogenemia in two unrelated Chinese families. Blood Coagul Fibrinolysis 2014; 25 (8) 894-897
  CrossrefPubMedGoogle Scholar
• 63 Zhu L, Wang M, Xie H, Jin Y, Yang L, Xu P. A novel fibrinogen mutation (γ Thr277Arg) causes hereditary hypofibrinogenemia in a Chinese family. Blood Coagul Fibrinolysis 2013; 24 (6) 642-644
  CrossrefPubMedGoogle Scholar
• 64 Wang Y, Zhu L, Hao X, Xie Y, Jin Y, Wang M. Unique de-novo mutation of fibrinogen gene in a Chinese girl with hypofibrinogenemia. Blood Coagul Fibrinolysis 2014; 25 (7) 780-782
  CrossrefPubMedGoogle Scholar
• 65 Vorjohann S, Fish RJ, Biron-Andréani C , et al. Hypodysfibrinogenaemia due to production of mutant fibrinogen alpha-chains lacking fibrinopeptide A and polymerisation knob ‘A’. Thromb Haemost 2010; 104 (5) 990-997
  Article in Thieme ConnectPubMedGoogle Scholar
• 66 Brennan SO, Davis RL, Lowen R, Ruskova A. Deletion of five residues from the coiled coil of fibrinogen (Bbeta Asn167_Glu171del) associated with bleeding and hypodysfibrinogenemia. Haematologica 2009; 94 (4) 585-588
  CrossrefPubMedGoogle Scholar
• 67 Brennan SO, Roncolato F. Novel fibrinogen (B β401Gly→Val) presents as dys- or hypodysfibrinogenaemia due to alterations in sialic acid content. Thromb Haemost 2011; 106 (3) 551-553
  Article in Thieme ConnectPubMedGoogle Scholar
• 68 Jayo A, Arnold E, González-Manchón C, Green D, Lord ST. Hypodysfibrinogenemia causing mild bleeding and thrombotic complications in a compound heterozygote of AalphaIVS4+1G>T mutation and Aalpha4841delC truncation (Aalpha(Perth)). Thromb Haemost 2009; 101 (4) 770-772
  PubMedGoogle Scholar
• 69 Ding Q, Ouyang Q, Xi X, Wang X, Shen Y, Wang H. Maternal chromosome 4 heterodisomy/isodisomy and Bβ chain Trp323X mutation resulting in severe hypodysfibrinogenaemia. Thromb Haemost 2012; 108 (4) 654-661
  Article in Thieme ConnectPubMedGoogle Scholar
• 70 Brennan SO, Davis RL, Chitlur M. New fibrinogen substitution (gammaSer313Arg) causes diminished gamma chain expression and hypodysfibrinogenaemia. Thromb Haemost 2010; 103 (2) 478-479
  PubMedGoogle Scholar
• 71 Cheah CY, Brennan SO, Kennedy H, Januszewicz EH, Maxwell E, Burbury K. Fibrinogen Melbourne: a novel congenital hypodysfibrinogenemia caused by γ326Cys-Phe in the fibrinogen γ chain, presenting as massive splanchnic venous thrombosis. Blood Coagul Fibrinolysis 2012; 23 (6) 563-565
  CrossrefPubMedGoogle Scholar
• 72 Ikeda M, Kobayashi T, Arai S , et al. Recombinant γT305A fibrinogen indicates severely impaired fibrin polymerization due to the aberrant function of hole ‘A’ and calcium binding sites. Thromb Res 2014; 134 (2) 518-525
  CrossrefPubMedGoogle Scholar
• 73 Ikeda M, Arai S, Mukai S, Takezawa Y, Terasawa F, Okumura N. Novel heterozygous dysfibrinogenemia, Sumida (AαC472S), showed markedly impaired lateral aggregation of protofibrils and mildly lower functional fibrinogen levels. Thromb Res 2015; 135 (4) 710-717
  CrossrefPubMedGoogle Scholar
• 74 Sugo T, Nakamikawa C, Takano H , et al. Fibrinogen Niigata with impaired fibrin assembly: an inherited dysfibrinogen with a Bbeta Asn-160 to Ser substitution associated with extra glycosylation at Bbeta Asn-158. Blood 1999; 94 (11) 3806-3813
  PubMedGoogle Scholar
• 75 Asselta R, Robusto M, Platé M, Santoro C, Peyvandi F, Duga S. Molecular characterization of 7 patients affected by dys- or hypo-dysfibrinogenemia: Identification of a novel mutation in the fibrinogen Bbeta chain causing a gain of glycosylation. Thromb Res 2015; 136 (1) 168-174
  CrossrefPubMedGoogle Scholar
• 76 Hua B, Li K, Lee A, Poon MC, Zhao Y. Coexisting congenital dysfibrinogenemia with a novel mutation in fibrinogen γ chain (γ322 Phe→Ile, Fibrinogen Beijing) and haemophilia B in a family. Haemophilia 2015; 21 (6) 846-851
  CrossrefPubMedGoogle Scholar
• 77 Martinez J, MacDonald KA, Palascak JE. The role of sialic acid in the dysfibrinogenemia associated with liver disease: distribution of sialic acid on the constituent chains. Blood 1983; 61 (6) 1196-1202
  PubMedGoogle Scholar
• 78 Lefebvre P, Velasco PT, Dear A , et al. Severe hypodysfibrinogenemia in compound heterozygotes of the fibrinogen AalphaIVS4 + 1G>T mutation and an AalphaGln328 truncation (fibrinogen Keokuk). Blood 2004; 103 (7) 2571-2576
  CrossrefPubMedGoogle Scholar
• 79 Meyer M, Dietzel H, Kaetzel R, Schmidt D, Liebscher K, Brennan SO. Fibrinogen Leipzig II (gamma351Gly—>Ser and gamma82Ala—>Gly): hypodysfibrinogenaemia due to two independent amino acid substitutions within the same polypeptide chain. Thromb Haemost 2007; 98 (4) 903-905
  PubMedGoogle Scholar
• 80 Ridgway HJ, Brennan SO, Faed JM, George PM. Fibrinogen Otago: a major alpha chain truncation associated with severe hypofibrinogenaemia and recurrent miscarriage. Br J Haematol 1997; 98 (3) 632-639
  CrossrefPubMedGoogle Scholar
• 81 Koopman J, Haverkate F, Grimbergen J, Egbring R, Lord ST. Fibrinogen Marburg: a homozygous case of dysfibrinogenemia, lacking amino acids A alpha 461-610 (Lys 461 AAA—>stop TAA). Blood 1992; 80 (8) 1972-1979
  PubMedGoogle Scholar